Q4 2025 Management View CEO Joseph Ciaffoni stated that 2025 was a transition year, highlighting the successful completion of Phase I Generate Momentum and the delivery of record net revenue for ...

Thanks, Jason, good morning and thank you for joining us on today's call to review our fourth quarter and full year 2025 results. Last July, we rolled out the Indivior Action Agenda to maximize the ...

The company raised its 2025 guidance, with Ciaffoni indicating, "We now expect total net revenue in 2025 to be up versus 2024, driven by SUBLOCADE growth of 10% at the midpoint." Preblick stated, "Our ...

Attributed 2025 performance to improved commercial execution and record SUBLOCADE net revenue of $856 million, a 13% year-over-year increase. Simplified the organizational structure to establish a ...

As it works to send opioid use disorder (OUD) treatment Sublocade back into its prior growth territory, Indivior is switching up its commercial team. The Virginia-based pharma has appointed Patrick ...